Skip to content
FDA: press announcements (US)·PickAI score62

FDA seeks public input on early-phase ibogaine trial design

FDA Seeks Public Input to Support Ibogaine Research

AI summary

The US has issued a request for information on approaches it is considering for the design of early-phase clinical trials of ibogaine drug products, and is seeking public comment.

Why it matters

The request sets out the protocol questions the agency wants answered, including a starting dose cap, so researchers and sponsors can see what evidence the FDA expects before early-phase ibogaine trials proceed.

Key facts

Compound
Ibogaine
Conditions
PTSD, Addiction
Jurisdiction
United States
Source
FDA: press announcements (US) (fda.gov)
Published
How this summary was made

The summary and the “Why it matters” note were written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: FDA: press announcements (US) · fda.gov

Connected to

Compound
Ibogaine
Conditions
PTSDAddiction
Jurisdiction
United States